Log In
Print
BCIQ
Print
Print this Print this
 

ORY-1001

  Manage Alerts
Collapse Summary General Information
Company Oryzon Genomics S.A.
DescriptionInhibitor of lysine-specific histone demethylase 1 (KDM1A; LSD1)
Molecular Target Lysine-specific demethylase 1 (KDM1A) (LSD1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

EU - Orphan Drug (Treat acute myelogenous leukemia (AML))

Partner

Roche


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today